Clinical Trial

Improving HIV-1 Control in Africa with Long Acting Antiretrovirals

Study acronym: IMPALA
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated September 27, 2024 (before its estimated April 2025 completion). Its status may not reflect the trial's current state.
Summary
IMPALA is a randomized, open-label, multicenter, interventional study of 540 virologically suppressed HIV-1 infected adults who have a history of sub-optimal adherence to daily oral ART and/or engagement in HIV care. The study will seek to demonstrate non-inferior antiviral effectiveness of the 2-monthly long-acting injectable combination of cabotegravir/rilpivirine as compared to continuation of first line oral antiretroviral therapy.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2022-09-16; most recent amendment 2024-09-25.
Status change: Recruiting → Active, Not Recruiting 2024-09-25
Status change: Not Yet Recruiting → Recruiting 2023-02-01
Trial Details
NCT Number NCT05546242
Lead Sponsor MRC/UVRI and LSHTM Uganda Research Unit
Collaborators: Janssen Pharmaceuticals
Conditions HIV-1-infection
Enrollment 540 participants
Start Date 2022-12-08
Primary Completion 2025-04 (estimated)
Study Completion 2026-03 (estimated)
Updated on ClinicalTrials.gov 2024-09-27